Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2-advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.

被引：0

作者：

Kalinsky, Kevin ^{[1
]}

Bianchini, Giampaolo ^{[2
]}

Hamilton, Erika P. ^{[3
]}

Graff, Stephanie L. ^{[4
]}

Park, Kyong Hwa ^{[5
]}

Jeselsohn, Rinath ^{[6
]}

Demirci, Umut ^{[7
]}

Martin, Miguel ^{[8
,9
]}

Layman, Rachel M. ^{[10
]}

Hurvitz, Sara A. ^{[11
,12
]}

Sammons, Sarah L. ^{[6
]}

Kaufman, Peter A. ^{[13
]}

Munoz, Montserrat ^{[9
,14
]}

Tseng, Ling-Ming ^{[15
]}

Knoderer, Holly ^{[16
]}

Nguyen, Bastien ^{[16
]}

Zhou, Yanhong ^{[16
]}

Ravenberg, Elizabeth ^{[16
]}

Litchfield, Lacey M. ^{[16
]}

Wander, Seth Andrew ^{[17
]}

机构：

[1] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[2] IRCCS Osped San Raffaele, Milan, Italy

[3] Sarah Cannon Res Inst, Nashville, TN USA

[4] Brown Univ, Lifespan Canc Inst, Legorreta Canc Ctr, Providence, RI USA

[5] Korea Univ, Anam Hosp, Dept Internal Med, Div Med Oncol,Coll Med, Seoul, South Korea

[6] Dana Farber Canc Inst, Boston, MA USA

[7] Uskudar Univ, Fac Med, Mem Ankara Hosp, Med Oncol, Ankara, Turkiye

[8] Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain

[9] GEICAM Spanish Breast Canc Grp, Madrid, Spain

[10] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[11] Univ Washington, Sch Med, Seattle, WA USA

[12] Fred Hutchinson Canc Ctr, Seattle, WA USA

[13] Univ Vermont, Canc Ctr, Burlington, VT 05405 USA

[14] Hosp Clin Barcelona, Barcelona, Spain

[15] Taipei Vet Gen Hosp, Taipei, Taiwan

[16] Eli Lilly & Co, Indianapolis, IN USA

[17] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 17_SUPPL期

关键词：

D O I：

10.1200/JCO.2024.42.17_suppl.LBA1001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：LBA1001 / LBA1001

页数：1

共 50 条

[21] MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2-advanced breast cancer: the multinational randomized phase III study
Zhang, Qing Yuan
Sun, Tao
Yin, Yong Mei
Li, Hui Ping
Yan, Min
Tong, Zhong Sheng
Oppermann, Christina P.
Liu, Yun Peng
Costa, Romulo
Li, Man
Cheng, Ying
Ouyang, Qu Chang
Chen, Xi
Liao, Ning
Wu, Xin Hong
Wang, Xiao Jia
Feng, Ji Feng
Hegg, Roberto
Kanakasetty, G. B.
Coccia-Portugal, Maria A.
Han, Ru Bing
Lu, Yi
Chi, Hai Dong
Jiang, Ze Fei
Hu, Xi Chun
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
[22] Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2-advanced breast cancer: a real-world evidence cohort
Sanchez-Bayona, Rodrigo
de Sa, Alfonso Lopez
Gilarranz, Yolanda Jerez
de Torre, Ana Sanchez
Alva, Manuel
Echavarria, Isabel
Moreno, Fernando
Tolosa, Pablo
Lopez, Blanca Herrero
de Luna, Alicia
Lema, Laura
Casado, Salvador Gamez
Madariaga, Ainhoa
Lopez-Tarruella, Sara
Manso, Luis
Bueno-Muino, Coralia
Garcia-Saenz, Jose A.
Ciruelos, Eva
Martin, Miguel
BREAST CANCER RESEARCH AND TREATMENT, 2024, 206 (03) : 551 - 559
[23] Phase 2 Study of the CDK4/6 Inhibitor FCN-437c in Combination With Fulvestrant or Letrozole and Goserelin in Patients With HR+, HER2-Advanced Breast Cancer
Shi, JiaJie
Li, Wei
Tong, Zhongsheng
Zang, Aimin
Zeng, Xiaohua
Wang, Shui
Huang, Tao
Wang, Ying
Song, Yanqiu
Kang, Lihua
Lv, Zheng
Shi, Yehui
Yang, Hua
Wu, Jing
Yin, Yongmei
Liang, Yan
Tan, Jie
Ming, Jie
Yang, Yaping
Luo, Simin
Gui, Xiujuan
Hui, Ai-Min
Wu, Zhuli
Tian, Ling
Yang, Yuchen
Diao, Lei
Zhang, Wenjing
Zhang, Yongjiao
Liu, Yunjiang
CANCER RESEARCH, 2023, 83 (05)
[24] Health-related quality of life (HRQoL) in MONARCH 2: Abemaciclib plus fulvestrant in women with HR+, HER2-advanced breast cancer (ABC) who progressed on endocrine therapy
Kaufman, Peter A.
Toi, Masakazu
Neven, Patrick
Sohn, Joohyuk
Price, Gregory L.
Lin, Yong
Boye, Mark
Li, Li
Gable, Jonathon
Carter, Gebra Cuyun
Sledge, George W.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[25] A real-world evidence study of everolimus plus endocrine therapy beyond CDK4/6 inhibitors for HR+/HER2-advanced breast cancer
Sanchez-Bayona, Rodrigo
Alva, Manuel
de Sa, Alfonso Lopez
Gilarranz, Yolanda Jerez
de Torre, Ana Sanchez
Tolosa, Pablo
de Luna, Alicia
Lopez-Tarruella, Sara
Lema, Laura
Moreno, Fernando
Echavarria, Isabel
Madariaga, Ainhoa
Benitez, Javier
Herrero, Blanca
Rey, Macarena
Ortega, Justo
Gamez, Salvador
Modrego, Andrea
Lozano, Rocio Martin
Figuero-Perez, Luis
Jimenez, Roberto
Sevilla, Marta Gonzalez
Gonzalez, Irene
Beranek, Marianela Bringas
de Toro, Maria
Massarrah, Tatiana
del Monte-Millan, Maria
Pinardo, Marina
Manso, Luis
Bueno-Muino, Coralia
Garcia-Saenz, Jose Angel
Martin, Miguel
Ciruelos, Eva
CANCER RESEARCH, 2023, 83 (05)
[26] MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
Sledge, George W., Jr.
Toi, Masakazu
Neven, Patrick
Sohn, Joohyuk
Inoue, Kenichi
Pivot, Xavier
Burdaeva, Olga
Okera, Meena
Masuda, Norikazu
Kaufman, Peter A.
Koh, Han
Grischke, Eva-Maria
Frenzel, Martin
Lin, Yong
Barriga, Susana
Smith, Ian C.
Bourayou, Nawel
Llombart-Cussac, Antonio
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (25) : 2875 - +
[27] A randomized trial of abemaciclib in combination with fulvestrant compared to chemotherapy in women with HR+, HER2-advanced breast cancer with visceral metastases
Kaufman, Peter
Glaspy, John
Zhang, Wei
Koustenis, Andrew
Chen, Yanyun
Brufsky, Adam
CANCER RESEARCH, 2020, 80 (04)
[28] Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer
Tolaney, Sara M.
Im, Young-Hyuck
Calvo, Emiliano
Lu, Yen-Shen
Hamilton, Erika
Forero-Torres, Andres
Bachelot, Thomas
Maur, Michela
Fasolo, Angelica
Tiedt, Ralph
Nardi, Lisa
Stammberger, Uz
Abdelhady, Ahmed M.
Ruan, Shiling
Lee, Soo Chin
CLINICAL CANCER RESEARCH, 2021, 27 (02) : 418 - 428
[29] Phase II trial of fulvestrant plus enzalutamide in ER+/Her2-advanced breast cancer
Elias, Anthony D.
Spoelsta, Nicole
Vidal, Gregory A.
Sams, Sharon
Kabos, Peter
Diamond, Jennifer R.
Shagisultanova, Elena
Afghahi, Anosheh
Mayordomo, Jose
McSpadden, Tessa
Crawford, Gloria
Carter, Lisa
Zolman, Kathryn
Armstead, Stephanie
Winchester, Alyse
Borges, Virginia
Wulfkuhle, Julia
Petricoin, Emanuel
Gao, Dexiang
Richer, Jennifer
CANCER RESEARCH, 2021, 81 (04)
[30] Dalpiciclib plus fulvestrant in HR+/HER2-advanced breast cancer (ABC): Updated analysis from the phase III DAWNA-1 trial
Zhang, P.
Zhang, Q. Y.
Hu, X.
Li, W.
Tong, Z.
Sun, T.
Teng, Y.
Wu, X.
Ouyang, Q.
Yan, X.
Cheng, J.
Liu, Q.
Feng, J.
Wang, X.
Xu, G.
Wu, F.
Xia, B.
Xu, B.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S642 - S643

← 1 2 3 4 5 →